THERAPY DOSSIER · th-b7fc768d5214

Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)

Biologic · Cell therapy (umbilical cord blood-derived MSCs); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (umbilical cord blood-derived MSCs); not a ChEMBL entity
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06078059 ↗NAcompleted

Allogeneic MSCs (UCB-MSCs) in Knee Osteoarthritis

Knee Osteoarthritis

Enrolment: 30 · Results not recorded

NCT03676400 ↗NAcompleted

Conditioned Media of Umbilical Cord Blood-derived Stem Cells for Androgenic Alopecia

Androgenic Alopecia

Enrolment: 84 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23333483 ↗2013Reported benefit

Mitigating effects of hUCB-MSCs on the hematopoietic syndrome resulting from total body irradiation.

MouseRadiationBALB/cFemaleAfter irradiation; exact interval not stated

Model: Total body irradiation, 7 Gy cobalt-60 gamma rays

hUCB-MSCs increased peripheral leukocyte, lymphocyte and monocyte recovery, increased bone marrow Ki-67 immunoreactivity at 3 weeks and modulated plasma Flt-3L and TGF-beta1 more effectively than G-CSF.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…